Literature DB >> 1573980

A model for planning optimal follow-up for outpatients on warfarin anticoagulation. Warfarin Optimal Outpatient Follow-up Study Group.

D L Kent1, D Vermes, M McDonell, J Henikoff, S D Fihn.   

Abstract

Patients taking warfarin for long-term anticoagulation require frequent clinic visits to monitor the prothrombin time ratio (PTR), a measure of blood clotting. A dynamic stochastic model using nonlinear optimization was developed to select follow-up visit intervals that minimize the overall costs of patient care. Assuming that fluctuations in a patient's PTR behave as a random diffusion process, future PTR fluctuations are unknown, except as revealed by past PTRs. To determine the incidence and costs of complications in relation to PTR, the authors reviewed the charts of 216 patients who had 719 patient-years of follow-up with 695 trivial, significant, life-threatening, or fatal complications. They modeled the relationship between costs of complications and deviation of the PTR from the therapeutic target as a fourth-order convex polynomial. The model is used to compute the interval to the next follow-up visit to minimize accumulated potential costs. Variables in the optimization are the cost of a monitoring visit and the expected costs of complications. The latter are derived from the current PTR, the variability of the patient's past PTR values, the number of past PTRs available, and the target PTR for the patient. No attempt is made to predict the level of the next PTR or suggest adjustments in the warfarin dose. Shorter follow-up is recommended for patients who have histories of large fluctuations in past PTRs and for patients with few prior PTR determinations. As visits accumulate, the patient's degree of variability can be estimated more accurately and visit intervals adjusted accordingly. The scheduling method balances costs to the health care system of monitoring each patient against the expected costs of complications. This approach has the potential to reduce the number of monitoring visits necessary for safe management of anticoagulated patients with stable PTRs and to improve control among unstable patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1573980     DOI: 10.1177/0272989X9201200206

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  8 in total

Review 1.  Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?

Authors:  F Peys
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 2.  Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?

Authors:  F Peys
Journal:  Pharm World Sci       Date:  1997-04

3.  Effectiveness of warfarin among patients with cancer.

Authors:  Adam J Rose; Jeff P Sharman; Al Ozonoff; Lori E Henault; Elaine M Hylek
Journal:  J Gen Intern Med       Date:  2007-05-03       Impact factor: 5.128

4.  A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics.

Authors:  S D Fihn; M B McDonell; D Vermes; J G Henikoff; D C Martin; C M Callahan; D L Kent; R H White
Journal:  J Gen Intern Med       Date:  1994-03       Impact factor: 5.128

5.  Setting the revisit interval in primary care.

Authors:  L M Schwartz; S Woloshin; J H Wasson; R A Renfrew; H G Welch
Journal:  J Gen Intern Med       Date:  1999-04       Impact factor: 5.128

6.  Visit frequency and hypertension.

Authors:  Richard Guthmann; Nancy Davis; Matthew Brown; Jose Elizondo
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-06       Impact factor: 3.738

7.  Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis.

Authors:  Eleonora Camilleri; Nienke van Rein; Felix J M van der Meer; Melchior C Nierman; Willem M Lijfering; Suzanne C Cannegieter
Journal:  Res Pract Thromb Haemost       Date:  2021-10-13

8.  Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma.

Authors:  Vivek Nair; Samuel Auger; Sara Kochanny; Frederick M Howard; Daniel Ginat; Olga Pasternak-Wise; Aditya Juloori; Matthew Koshy; Evgeny Izumchenko; Nishant Agrawal; Ari Rosenberg; Everett E Vokes; M Reza Skandari; Alexander T Pearson
Journal:  JAMA Netw Open       Date:  2022-04-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.